Investee Company News

March 19, 2019 Novan and Sato Advance Japan Market and Dermatology Partnership March 13, 2019 Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results March 11, 2019 Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates March 5, 2019 Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 February 20, 2019 Mayo Clinic Study Reports 47% Reduction in C.diff Infection Rates Using Pulsed Xenon UV Room Disinfection February 13, 2019 Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks February 7, 2019 Altan Pharma Submits New Drug Application for Acetaminophen Solution for Infusion for Treatment of Pain and Reduction of Fever February 4, 2019 Melinta Therapeutics Provides Corporate Updates January 30, 2019 Novan Provides Business Update January 22, 2019 Wren Therapeutics completes £18 million Series A financing January 15, 2019 Immunocore names David Berman as Head of R&D January 4, 2019 Immunocore appoints Bahija Jallal as Chief Executive Officer January 4, 2019 Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions January 2, 2019 Novan Announces Management Changes and Provides Business Update December 19, 2018 Melinta Therapeutics Announces Commitment for New Credit Facility of Up to $135 Million ~ December 19, 2018 John H. Johnson Agrees to Become Permanent Chief Executive Officer of Melinta Therapeutics December 11, 2018 Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit December 10, 2018 Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily December 4, 2018 Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting November 30, 2018 Kymab granted leave to appeal to the UK Supreme Court November 29, 2018 Poseida Therapeutics to Provide Update on Phase 1 Study of P-BCMA-101 at the 2018 American Society of Hematology Annual Meeting November 27, 2018 Melinta Therapeutics Granted European Commission Marketing Authorization for Vabomere® (meropenem and vaborbactam) November 19, 2018 Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech November 14, 2018 Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results November 12, 2018 Novan Announces Corporate Update Conference Call and Webcast November 7, 2018 Melinta Therapeutics Reports Third Quarter 2018 Financial Results November 5, 2018 Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-101 October 31, 2018 Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors October 29, 2018 Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP October 25, 2018 Novan Creates Dedicated Women’s Health Business Unit